Alison Moore's Insider Trades & SAST Disclosures
Alison Moore's most recent trade in Codexis Inc. was a trade of 161,250 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 5, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Alison Moore.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Codexis Inc. | Alison Moore | Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2025 | 161,250 | 161,250 | - | - | Stock Option (Right to Buy) | |
| Codexis Inc. | Alison Moore | Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2025 | 26,875 | 175,571 (0%) | 0% | 0 | Common Stock | |
| Codexis Inc. | Alison Moore | Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Oct 2024 | 300,000 | 300,000 | - | - | Stock Option (Right to Buy) | |
| Codexis Inc. | Alison Moore | Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Oct 2024 | 50,000 | 148,696 (0%) | 0% | 0 | Common Stock | |
| Codexis Inc. | Alison Moore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 30,120 | 98,696 (0%) | 0% | 0 | Common Stock | |
| Codexis Inc. | Alison Moore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 34,602 | 68,576 (0%) | 0% | 0 | Common Stock | |
| Allogene Therapeutics Inc | Alison Moore | Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Mar 2023 | 558,094 | 672,731 (0%) | 0% | 0 | Common Stock | |
| Allogene Therapeutics Inc | Alison Moore | Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Mar 2023 | 432,738 | 432,738 | - | - | Stock Option (Right to buy) | |
| Allogene Therapeutics Inc | Alison Moore | Chief Technical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.51 per share. | 14 Mar 2023 | 8,351 | 114,637 (0%) | 0% | 5.5 | 45,990 | Common Stock |
| Codexis Inc. | Alison Moore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 11,273 | 33,974 (0%) | 0% | 0 | Common Stock | |
| Allogene Therapeutics Inc | Alison Moore | Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Mar 2022 | 737,179 | 737,179 | - | - | Stock Option (Right to Buy) | |
| Allogene Therapeutics Inc | Alison Moore | Chief Technical Officer | Sale of securities on an exchange or to another person at price $ 7.63 per share. | 15 Mar 2022 | 8,698 | 120,430 (0%) | 0% | 7.6 | 66,388 | Common Stock |
| Codexis Inc. | Alison Moore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2021 | 4,796 | 22,701 (0%) | 0% | 0 | Common Stock | |
| Allogene Therapeutics Inc | Alison Moore | Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2021 | 92,365 | 92,365 | - | - | Stock Option (Right to Buy) | |
| Allogene Therapeutics Inc | Alison Moore | Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2021 | 24,866 | 127,440 (0%) | 0% | 0 | Common Stock | |
| Allogene Therapeutics Inc | Alison Moore | Chief Technical Officer | Sale of securities on an exchange or to another person at price $ 38.14 per share. | 15 Mar 2021 | 6,164 | 102,574 (0%) | 0% | 38.1 | 235,089 | Common Stock |
| Allogene Therapeutics Inc | Alison Moore | Chief Technical Officer | Sale of securities on an exchange or to another person at price $ 42.00 per share. | 12 Oct 2020 | 24,233 | 108,370 (0%) | 0% | 42 | 1,017,786 | Common Stock |
| Allogene Therapeutics Inc | Alison Moore | Chief Technical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Oct 2020 | 24,233 | 590,990 | - | - | Stock Option (Right to Buy) | |
| Allogene Therapeutics Inc | Alison Moore | Chief Technical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.27 per share. | 12 Oct 2020 | 24,233 | 132,603 (0%) | 0% | 2.3 | 55,009 | Common Stock |
| Allogene Therapeutics Inc | Alison Moore | Chief Technical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Oct 2020 | 11,031 | 579,959 | - | - | Stock Option (Right to Buy) | |
| Allogene Therapeutics Inc | Alison Moore | Chief Technical Officer | Sale of securities on an exchange or to another person at price $ 42.00 per share. | 12 Oct 2020 | 11,031 | 108,370 (0%) | 0% | 42 | 463,302 | Common Stock |
| Allogene Therapeutics Inc | Alison Moore | Chief Technical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.27 per share. | 12 Oct 2020 | 11,031 | 119,401 (0%) | 0% | 2.3 | 25,040 | Common Stock |
| Allogene Therapeutics Inc | Alison Moore | Chief Technical Officer | Sale of securities on an exchange or to another person at price $ 41.00 per share. | 08 Oct 2020 | 39,509 | 108,370 (0%) | 0% | 41 | 1,619,869 | Common Stock |
| Allogene Therapeutics Inc | Alison Moore | Chief Technical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Oct 2020 | 30,199 | 615,223 | - | - | Stock Option (Right to Buy) | |
| Allogene Therapeutics Inc | Alison Moore | Chief Technical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.27 per share. | 08 Oct 2020 | 30,199 | 147,879 (0%) | 0% | 2.3 | 68,552 | Common Stock |
| Allogene Therapeutics Inc | Alison Moore | Chief Technical Officer | Sale of securities on an exchange or to another person at price $ 41.00 per share. | 08 Oct 2020 | 5,065 | 117,680 (0%) | 0% | 41 | 207,665 | Common Stock |
| Allogene Therapeutics Inc | Alison Moore | Chief Technical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Oct 2020 | 5,065 | 645,422 | - | - | Stock Option (Right to Buy) | |
| Allogene Therapeutics Inc | Alison Moore | Chief Technical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.27 per share. | 08 Oct 2020 | 5,065 | 122,745 (0%) | 0% | 2.3 | 11,498 | Common Stock |
| Allogene Therapeutics Inc | Alison Moore | Chief Technical Officer | Sale of securities on an exchange or to another person at price $ 40.00 per share. | 06 Oct 2020 | 44,574 | 117,680 (0%) | 0% | 40 | 1,782,960 | Common Stock |
| Allogene Therapeutics Inc | Alison Moore | Chief Technical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Oct 2020 | 35,264 | 650,487 | - | - | Stock Option (Right to Buy) | |
| Allogene Therapeutics Inc | Alison Moore | Chief Technical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.27 per share. | 06 Oct 2020 | 35,264 | 161,536 (0%) | 0% | 2.3 | 80,049 | Common Stock |
| Allogene Therapeutics Inc | Alison Moore | Chief Technical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Aug 2020 | 32,451 | 685,751 | - | - | Stock Option (Right to Buy) | |
| Allogene Therapeutics Inc | Alison Moore | Chief Technical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.27 per share. | 13 Aug 2020 | 32,451 | 126,272 (0%) | 0% | 2.3 | 73,664 | Common Stock |
| Codexis Inc. | Alison Moore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2020 | 17,905 | 17,905 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges